Creekmur Asset Management LLC Lowers Position in DaVita Inc. (NYSE:DVA)

Creekmur Asset Management LLC cut its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 27.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,898 shares of the company's stock after selling 1,822 shares during the quarter. Creekmur Asset Management LLC's holdings in DaVita were worth $749,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of DVA. Invesco Ltd. lifted its stake in shares of DaVita by 20.9% in the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after buying an additional 275,284 shares in the last quarter. Northern Trust Corp lifted its stake in shares of DaVita by 12.5% in the fourth quarter. Northern Trust Corp now owns 740,774 shares of the company's stock valued at $110,783,000 after buying an additional 82,326 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of DaVita by 14.0% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 466,046 shares of the company's stock valued at $69,697,000 after buying an additional 57,386 shares in the last quarter. Deutsche Bank AG lifted its stake in shares of DaVita by 35.2% in the fourth quarter. Deutsche Bank AG now owns 392,422 shares of the company's stock valued at $58,687,000 after buying an additional 102,230 shares in the last quarter. Finally, Epoch Investment Partners Inc. bought a new position in shares of DaVita in the fourth quarter valued at $55,100,000. 90.12% of the stock is owned by institutional investors.

DaVita Price Performance

NYSE:DVA traded down $2.25 during mid-day trading on Friday, hitting $141.13. 708,797 shares of the stock traded hands, compared to its average volume of 810,218. The business's 50-day moving average price is $140.11 and its 200 day moving average price is $148.57. The company has a market cap of $10.66 billion, a PE ratio of 13.99, a price-to-earnings-growth ratio of 0.99 and a beta of 1.11. DaVita Inc. has a 12-month low of $131.76 and a 12-month high of $179.60. The company has a quick ratio of 1.20, a current ratio of 1.25 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The company reported $2.00 EPS for the quarter, topping the consensus estimate of $1.75 by $0.25. The business had revenue of $3.22 billion during the quarter, compared to analyst estimates of $3.22 billion. DaVita had a net margin of 6.63% and a return on equity of 176.11%. The company's revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the prior year, the business earned $2.26 EPS. On average, analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

DVA has been the subject of several analyst reports. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a report on Friday, April 25th. Truist Financial lowered their target price on shares of DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a report on Monday, May 19th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $164.50.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.